Brightgene Bio-medical Technology Co's quarterly Total Liabilities
increased
from Sep. 2025 (¥2,828.35 Mil) to Dec. 2025 (¥2,978.67 Mil) and
increased
from Dec. 2025 (¥2,978.67 Mil) to Mar. 2026 (¥3,633.47 Mil).
Brightgene Bio-medical Technology Co's annual Total Liabilities
increased
from Dec. 2023 (¥2,614.25 Mil) to Dec. 2024 (¥2,726.97 Mil) and
increased
from Dec. 2024 (¥2,726.97 Mil) to Dec. 2025 (¥2,978.67 Mil).
Brightgene Bio-medical Technology Co Total Liabilities Related Terms
Brightgene Bio-medical Technology Co Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co Total Liabilities Chart
Brightgene Bio-medical Technology Co Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co (SHSE:688166) has a Total Liabilities of ¥3,633 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Brightgene Bio-medical Technology Co and its competitors.
Is Brightgene Bio-medical Technology Co's Total Liabilities too high?
Brightgene Bio-medical Technology Co's current Total Liabilities is ¥3,633 Mil. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Total Liabilities compare to VRTX and REGN?
Brightgene Bio-medical Technology Co's Total Liabilities of ¥3,633 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Brightgene Bio-medical Technology Co and its competitors. Brightgene Bio-medical Technology Co's current Total Liabilities is ¥3,633 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.50, compared to a current price of ¥31.19 — trading 19% below its estimated fair value. The current Total Liabilities is ¥3,633 Mil. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Total Liabilities is ¥3,633 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued.
The current stock price of ¥31.19 is trading 19% below its estimated GF Value™ of ¥38.50.
GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688166:
Total Liabilities: ¥3,633 Mil
GF Value™: ¥38.50 vs. price of ¥31.19 (19% below fair value)
No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brightgene Bio-medical Technology Co Business Description
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score
Get the complete analysis for SHSE:688166
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688166 has been successfully added to your 
